This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge
by Kinjel Shah
The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.
Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study
by Kinjel Shah
Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.
Here's Why AstraZeneca (AZN) Stock is Up This Year So Far
by Zacks Equity Research
AstraZeneca's (AZN) shares are up this year mainly due to rapid progress in its efforts to make a vaccine to treat COVID-19 as well as other positive pipeline and regulatory updates.
Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity
by Zacks Equity Research
Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.
J&J to Stop Development of Influenza Candidate Pimodivir
by Zacks Equity Research
Johnson & Johnson (JNJ) to halt the development of pimodivir, an investigational antiviral treatment of influenza A infection.
Innoviva (INVA) in Focus: Stock Moves 7% Higher
by Zacks Equity Research
Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?
by Sanghamitra Saha
The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.
Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg
by Zacks Equity Research
Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.
AstraZeneca's Imfinzi Gets EU Approval for First-Line SCLC
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi gets approval in Europe to treat extensive-stage small cell lung cancer.
The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK
Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bayer Submits Application for Heart Failure Drug in China
by Zacks Equity Research
Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.
Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates
by Kinjel Shah
AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.
Top Analyst Reports for Salesforce, Merck & AT&T
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including salesforce.com (CRM), Merck Co. (MRK) and AT&T (T).
Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK
5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks
by Sweta Killa
While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.
Merck's Keytruda Gets Approval for Esophageal Cancer in Japan
by Zacks Equity Research
Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.
Dow Reclaims 28,000: 5 Stocks Driving the ETF Rally
by Sweta Killa
The Dow Jones Industrial Index ended above 28,000 for the first time in six months.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
Merck's Keytruda Positive in First-Line Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.
Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors
by Zacks Equity Research
Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.
AstraZeneca's Imfinzi Gets Priority Tag for 4-Week Dosing
by Zacks Equity Research
The FDA grants priority review to AstraZeneca's (AZN) sBLA seeking approval of Imfinzi for a four-week fixed-dose regimen for its approved indications in bladder cancer and non-small cell lung cancer.
Bristol Myers & Dragonfly Team Up for Immunotherapy Program
by Zacks Equity Research
Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.
Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates
by Kinjel Shah
Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).